Aspira Pathlab & Diagnostics Ltd
Ticker: ASPIRA
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
64.86
Market Cap
66.76
Debt/Equity
0.1488
ROE %
16.429
PB
4.9933
Promoter %
18.391
Pledge %
0.000
1Y Rev Growth %
64.391
5Y Rev Growth %
NP Margin %
9.022
NP Margin 5Y Avg %
Trading Reference
1M Return %
3.969
6M Return %
8.516
1Y Return %
38.000
% Away 52W High
64.632
% Away 52W Low
45.263
Daily Volume
9999
Investment Verdict
Hold
Score 62/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 32/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Aspira Pathlab & Diagnostics Ltd is currently trading near a key support level, with recent volume indicating increased interest. If it breaks above the resistance level at 150, it could see a potential upside. However, if it falls below the support at 120, there could be significant downside risk.
Upside Probability: 20% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
G
Golden Tobacco Ltd
Golden Tobacco Ltd presents significant risks due to industry challenges and inconsistent financial performance.
View details
L
Lakshmi Finance and Industrial Corp Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Archies Ltd
Archies Ltd presents several challenges, including inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
R
Relicab Cable Manufacturing Ltd
Relicab Cable Manufacturing Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
G
Genesis IBRC India Ltd
The stock presents significant risks with limited growth prospects and weak financials.
View details
E
Ecoboard Industries Ltd
Ecoboard Industries Ltd presents several risks with limited growth prospects and profitability concerns, making it a risky investment at this time.
View details
O
Onix Solar Energy Ltd
Onix Solar Energy Ltd presents a risky investment due to inconsistent growth and profitability metrics, along with governance concerns.
View details
B
Bombay Metrics Supply Chain Ltd
The stock presents significant risks with inconsistent growth and profitability metrics, alongside valuation concerns.
View details
V
Vasundhara Rasayans Ltd
Vasundhara Rasayans Ltd shows potential in a growing sector, but faces challenges in profitability and valuation. Caution is advised.
View details
F
Flex Foods Ltd
Flex Foods Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should be cautious.
View details
A
AmpVolts Ltd
AmpVolts Ltd shows potential in a growing sector but faces challenges in profitability and valuation. Caution is advised.
View details
T
Trustedge Capital Ltd
Trustedge Capital Ltd shows potential but has several areas of concern that need addressing for a stronger outlook.
View details
G
Godavari Drugs Ltd
Godavari Drugs Ltd presents several risks with inconsistent growth and weak market sentiment, making it a risky investment at this time.
View details
U
Unison Metals Ltd
Unison Metals Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
S
Salasar Exteriors and Contour Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Annvrridhhi Ventures Ltd
The stock presents several risks, including inconsistent growth and weak profitability metrics, making it a risky investment.
View details
Business Overview
Aspira Pathlab & Diagnostics Ltd is a leading provider of diagnostic and pathology services in India, dedicated to delivering accurate and timely health insights. Catering to individuals, healthcare providers, and hospitals, Aspira plays a crucial role in early disease detection and management. With a commitment to quality and innovation, it empowers patients to make informed health decisions. Aspira's extensive network and advanced technology ensure reliable results, making it a trusted partner in healthcare.
- Leading diagnostic service provider in India
- Focus on accuracy and timely results
- Supports individuals and healthcare professionals
- Empowers informed health decisions
- Extensive network across the country
- Commitment to quality and innovation
Investment Thesis
Aspira Pathlab & Diagnostics Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth in digital services, and attractive valuation compared to peers. The company's robust foundation and innovative approach position it well for future expansion in the healthcare sector.
- Promoter group with a proven track record enhances investor confidence.
- Rapid growth in digital services aligns with healthcare trends and consumer preferences.
- Valuation metrics indicate Aspira is undervalued relative to industry peers.
- Strong demand for diagnostic services supports revenue growth potential.
- Strategic focus on technology integration positions the company for sustainable success.
Opportunity vs Risk
Opportunities
- Growing demand for diagnostic services
- Expansion into tier-2 cities
- Partnerships with healthcare providers
- Innovative testing technologies
- Strong brand recognition
Risks ⚠️
- Regulatory changes impacting operations
- Intense competition in diagnostics
- Economic downturn affecting spending
- Dependence on key management
- Technological disruptions in testing
Peer Perspective
Aspira Pathlab & Diagnostics Ltd trades at a discount to peers like Dr. Lal PathLabs and Thyrocare Technologies. A rerating could occur if it achieves consistent margin stability and accelerated revenue growth.
Future Outlook
Aspira Pathlab & Diagnostics Ltd is well-positioned for growth, driven by increasing demand for diagnostic services. Successful execution of strategic initiatives and effective cost control will be crucial to maximizing shareholder value.
AI FAQs for Retail Users
- Q: What does Aspira Pathlab & Diagnostics Ltd do?A: The company provides diagnostic services and laboratory testing for various medical conditions.
- Q: Is Aspira Pathlab a profitable company?A: Profitability can vary; check recent financial reports for the latest information.
- Q: What factors can affect Aspira Pathlab's stock price?A: Market demand, company performance, industry trends, and economic conditions can influence the stock price.
- Q: How can I invest in Aspira Pathlab shares?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: What are the risks of investing in Aspira Pathlab?A: Risks include market volatility, regulatory changes, and competition in the healthcare sector.
📊 Stock Investment Checklist (100 Points)
Aspira Pathlab & Diagnostics Ltd • Updated: 2025-09-17 01:17:30
-
10BusinessHighThe diagnostics sector is growing, but competition is intense.
-
10GrowthHighRevenue growth has been consistent, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
8ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity could be improved.
-
6GovernanceGoodPromoter holding is stable, but there are concerns about transparency.
-
5DriversGoodGrowth drivers exist, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Aspira Pathlab & Diagnostics Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 55/100
- Market Confidence: 68/100